Decitabine and its role in the treatment of hematopoietic malignancies

References

• Herman J G, Baylin S B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042–2054
   PubMed Web of Science ®Google Scholar
• Jones P A. Overview of cancer epigenetics. Semin Hematol 2005; 42(Suppl 2)S3–S8
   Google Scholar
• Barlow D P. Gametic imprinting in mammals. Science 1995; 270: 1610–1613
   PubMed Web of Science ®Google Scholar
• Csankovszki G, Nagy A, Jaenisch R. Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation. J Cell Biol 2001; 153: 773–784
   PubMed Web of Science ®Google Scholar
• Momparler R L. Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). Semin Oncol 2005; 32: 443–451
   Google Scholar
• Onetto N, Momparler R L, Momparler L F, Gyger M. In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2′-deoxycytidine. Semin Oncol 1987; 14(Suppl 1)231–237
   PubMed Web of Science ®Google Scholar
• Rosenfeld C S. Clinical development of decitabine as a prototype for an epigenetic drug program. Semin Oncol 2005; 32: 465–472
   PubMed Web of Science ®Google Scholar
• Lehmann U, Brakensiek K, Kreipe H. Role of epigenetic changes in hematological malignancies. Ann Hematol 2004; 83: 137–152
   PubMed Web of Science ®Google Scholar
• Herman J G, Civin C I, Issa J P, Collector M I, Sharkis S J, Baylin S B. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997; 57: 837–841
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Toyota M, Itoh F, Suzuki H, Obata T, Yamamoto H, et al. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene 2002; 21: 2741–2749
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Castillejo J A, Jimenez A, Gonzalez M G, Moreno F, Rodriguez Mdel C, et al. 5′CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 2002; 99: 2291–2296
   PubMed Web of Science ®Google Scholar
• Issa J P, Zehnbauer B A, Kaufmann S H, Biel M A, Baylin S B. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res 1997; 57: 1678–1681
   PubMed Web of Science ®Google Scholar
• Aggerholm A, Hokland P. DAP-kinase CpG island methylation in acute myeloid leukemia: methodology versus biology?. Blood 2000; 95: 2997–2999
   PubMed Web of Science ®Google Scholar
• Gattei V, Fonsatti E, Sigalotti L, Degan M, Di Giacomo A M, Altomonte M, Calabro L, Maio M. Epigenetic immunomodulation of hematopoietic malignancies. Semin Oncol 2005; 32: 503–510
   PubMed Web of Science ®Google Scholar
• Sigalotti L, Altomonte M, Colizzi F, Degan M, Rupolo M, Zagonel V, et al. 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. Blood 2003; 101: 4644–4646
   PubMed Web of Science ®Google Scholar
• Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992; 82: 358–367
   PubMed Web of Science ®Google Scholar
• Kufe D W, Holland J F, Frei E, Pollock R E, Weichselbaum R R, Bast R C, Gansler T S. Cancer Medicine, 6. BC Decker, Hamilton, ON 2003; 2: xxiv, 2699, 40
   Google Scholar
• Kantarjian H M, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007; 109: 265–273
   PubMed Web of Science ®Google Scholar
• Zagonel V, Lo Re G, Marotta G, Babare R, Sardeo G, Gattei V, et al. 5-Aza-2′-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 1993; 7(Suppl 1)30–35
   PubMed Web of Science ®Google Scholar
• Wijermans P W, Krulder J W, Huijgens P C, Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11: 1–5
   PubMed Web of Science ®Google Scholar
• Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000; 18: 956–962
   PubMed Web of Science ®Google Scholar
• Daskalakis M, Nguyen T T, Nguyen C, Guldberg P, Kohler G, Wijermans P, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957–2964
   PubMed Web of Science ®Google Scholar
• Ruter B, Wijermans P W, Lubbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 2006; 106: 1744–1750
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa J P, Rosenfeld C S, Bennett J M, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Kantarjian H, Pinto A, Schiffer C A, Nimer S D, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674
   PubMed Web of Science ®Google Scholar
• Rivard G E, Momparler R L, Demers J, Benoit P, Raymond R, Lin K, Momparler L F. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 1981; 5: 453–462
   PubMed Web of Science ®Google Scholar
• DeSimone J, Koshy M, Dorn L, Lavelle D, Bressler L, Molokie R, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 2002; 99: 3905–3908
   PubMed Web of Science ®Google Scholar
• Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N, et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 2000; 96: 2379–2384
   PubMed Web of Science ®Google Scholar
• Issa J P, Garcia-Manero G, Giles F J, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635–1640
   PubMed Web of Science ®Google Scholar
• Yang A S, Doshi K D, Choi S W, Mason J B, Mannari R K, Gharybian V, et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 2006; 66: 5495–5503
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Issa J P. Decitabine dosing schedules. Semin Hematol 2005; 42(Suppl 2)S17–S22
   Google Scholar
• Yang A S, Estecio M R, Doshi K, Kondo Y, Tajara E H, Issa J P. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004; 32: e38
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos C E, Issa J P. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007; 109: 1133–1137
   PubMed Web of Science ®Google Scholar
• O'Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
   PubMed Web of Science ®Google Scholar
• Cortes J, Rousselot P, Kim D W, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2006; 109: 3207–3213, Others
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, O'Brien S, Cortes J, Giles F J, Faderl S, Issa J P, et al. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003; 98: 522–528
   PubMed Web of Science ®Google Scholar
• Sacchi S, Kantarjian H M, O'Brien S, Cortes J, Rios M B, Giles F J, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999; 86: 2632–2641
   PubMed Web of Science ®Google Scholar
• Issa J P, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005; 23: 3948–3956
   PubMed Web of Science ®Google Scholar
• Oki Y, Kantarjian H M, Gharibyan V, Jones D, O'Brien S, Verstovsek S, Cortes J, Morris G M, Garcia-Manero G, Issa J P. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 2007; 109: 899–906
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989; 7: 1268–1274
   PubMed Web of Science ®Google Scholar
• Ruter B, Wijermans P W, Lubbert M. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol 2004; 80: 128–135
   PubMed Web of Science ®Google Scholar
• Momparler R L, Rivard G E, Gyger M. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther 1985; 30: 277–286
   PubMed Web of Science ®Google Scholar
• Pinto A, Zagonel V, Attadia V, Bullian P L, Gattei V, Carbone A, et al. 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 1989; 4(Suppl 3)28–32
   PubMed Web of Science ®Google Scholar
• Petti M C, Mandelli F, Zagonel V, De Gregoris C, Merola M C, Latagliata R, et al. Pilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 1993; 7(Suppl 1)36–41
   PubMed Web of Science ®Google Scholar
• Cashen A, Schiller G J, Larsen J S, Cullen M T, Jr, DiPersio J F. Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML). ASH Annu Meet Abstr 2006; 108: 1984
   Google Scholar
• Cameron E E, Bachman K E, Myohanen S, Herman J G, Baylin S B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103–107
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian H M, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108: 3271–3279
   PubMed Web of Science ®Google Scholar
• Gore S D. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat Clin Pract Oncol 2005; 2(Suppl 1)S30–S35
   PubMedGoogle Scholar
• de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, et al. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 2003; 97: 1242–1247
   PubMed Web of Science ®Google Scholar